Posted by Michael Wonder on 17 May 2018
Castle Creek Pharmaceuticals receives FDA rare paediatric disease designation for diacerein 1% ointment for epidermolysis bullosa
16 May 2018 - Castle Creek Pharmaceuticals today announced that the U.S. FDA has granted rare paediatric disease designation for diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa.
The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of patients with epidermolysis bullosa simplex, a subtype of epidermolysis bullosa.
Read Castle Creek Pharmaceuticals press release
